Objective: Alexander disease is a fatal leukodystrophy caused by autosomal dominant gain-of-function mutations in the gene for glial fibrillary acidic protein (GFAP), an intermediate filament protein primarily expressed in astrocytes of the central nervous system. A key feature of pathogenesis is overexpression and accumulation of GFAP, with formation of characteristic cytoplasmic aggregates known as Rosenthal fibers. Here we investigate whether suppressing GFAP with antisense oligonucleotides could provide a therapeutic strategy for treating Alexander disease. Methods: In this study, we use GFAP mutant mouse models of Alexander disease to test the efficacy of antisense suppression and evaluate the effects on molecular and cellular phenotypes and non-cell-autonomous toxicity. Antisense oligonucleotides were designed to target the murine Gfap transcript, and screened using primary mouse cortical cultures. Lead oligonucleotides were then tested for their ability to reduce GFAP transcripts and protein, first in wild-type mice with normal levels of GFAP, and then in adult mutant mice with established pathology and elevated levels of GFAP. Results: Nearly complete and long-lasting elimination of GFAP occurred in brain and spinal cord following single bolus intracerebroventricular injections, with a striking reversal of Rosenthal fibers and downstream markers of microglial and other stress-related responses. GFAP protein was also cleared from cerebrospinal fluid, demonstrating its potential utility as a biomarker in future clinical applications. Finally, treatment led to improved body condition and rescue of hippocampal neurogenesis.
Based on mouse models and cell cultures, GFAP mutations associated with AxD appear to produce a gain-offunction, 2 and a key step in pathogenesis is elevation of GFAP to a threshold that causes toxicity. 7, 8 In both mouse [8] [9] [10] and human, 11, 12 the levels of GFAP roughly correlate with disease severity (with severity defined in humans by age of onset).
Given the large number of disease-causing mutations, and the apparent minimal consequence of the null state in the mouse, we previously proposed general suppression of GFAP as an approach for therapy. 13 We have conducted screens to identify existing drugs capable of general suppression, using primary cultures of mouse astrocytes. 14 The resulting hits (such as clomipramine)
were active in wild-type (WT) mice but subsequently failed in mutant mice. Other known drugs under study such as ceftriaxone (for glutamate transporters) and lithium (to increase autophagy) either failed completely or were only modestly effective with unacceptable side effects. 15, 16 As an alternative, antisense oligonucleotides (ASOs) are rapidly becoming a realistic option for manipulating gene expression in the CNS. 17, 18 In mouse models of Huntington disease, the use of intracerebroventricular (ICV) infusion to bypass the blood-brain barrier led to long-lasting suppression by relatively short-term treatments. 19 ASOs for the treatment of spinal muscular atrophy (SMA) recently passed through phase III clinical trials and have been approved by the U.S. Food and Drug Administration. 20, 21 However, little is known about the accessibility of astrocytes to ASO delivery and the amenability of a highly expressed astrocyte target to ASO suppression.
In this report, we use ASOs to suppress GFAP in mouse models of AxD with remarkable results. Although rare, AxD is one of only a few primary disorders of astrocytes, and as such, specifically demonstrates astrocyte responsiveness to ASO treatment. More importantly, this is the first significant advance toward therapy for this devastating disease.
Materials and Methods

Mice
Mice of various strains were used in this study. WT strains included C57BL/6J (Jackson Laboratory, Bar Harbor, ME) and FVB/N (Taconic, Hudson, NY). Mice engineered with point mutations at the Gfap locus included the Gfap tm3Mes and Gfap tm2Mes lines, carrying the R76H and R236H mutations, respectively, and were maintained as heterozygotes congenic in the FVB/N or B6 genetic backgrounds. 8 Reporter mice created with an exogenous transgene consisting of 12kb of the murine Gfap promoter driving a luciferase gene 22 were maintained as hemizygotes (FVB/N-Tg[Gfap-luc]53Xen 
Delivery of ASOs
ASOs were dissolved at 100mg/ml in sterile phosphate-buffered saline (PBS) or 0.9% sterile saline and delivered by a single ICV bolus injection into the right lateral ventricle of adult mice. Anesthetized animals were positioned in a stereotaxic apparatus, and scalps were prepared by cleaning the clipped area with Betadine and 70% ethanol rinse. A 1-to 1.5cm, slightly off-center incision was made in the scalp. A Hamilton syringe primed with 10 ml of injection solution was positioned over bregma. The needle of the syringe was moved to the appropriate anterior/posterior and medial/lateral coordinates. For ICV bolus injections, the coordinates 0.3mm anterior/posterior (anterior to bregma) and 1.0mm medial/lateral to the right are used. The needle tip was advanced through the skull to 23.0mm from the skull surface. The proper amount of injection solution (10 ll) was injected by hand at approximately 1 ll/s. After 3 minutes, the needle was withdrawn from the skull and the incision was sutured closed.
Collection of Cerebrospinal Fluid
Cerebrospinal fluid (CSF) was collected from mice according to the method of DeMattos et al. 23 Mice were anaesthetized with a mixture of ketamine, xylazine, and acepromazine, via intraperitoneal injection. A midline sagittal incision was made over the dorsal aspect of the hindbrain, and 3 muscle layers were carefully peeled back to expose the cisterna magna. The membrane covering the cisterna magna was pierced with a borosilicate glass micropipette, and CSF was collected immediately. Approximately 10 ll of CSF was collected per animal, and stored at 280 8C until further processing.
RNA Analysis
Animals were sacrificed by CO 2 asphyxiation, and CNS regions were microdissected and rapidly frozen on dry ice. For the initial dose-response and time course experiments in WT mice (Fig 1) Table. For additional experiments in mutant mice (Fig. 2 ), tissues were homogenized in Trizol and processed according to the manufacturer's protocol (Invitrogen, Thermo Fisher Scientific). Contra-and ipsilateral regions were homogenized separately. Complementary DNA was synthesized from 1 mg total RNA with Superscript III (Invitrogen, Thermo Fisher Scientific), and qPCR was performed with SYBR Select Master Mix on a ViiA7 Real Time PCR System (Applied Biosystems, Foster City, CA; Thermo Fisher Scientific). Primer sets are listed in the Table, and values were normalized to 18S rRNA (Rn18s). No differences were observed between contra-and ipsilateral regions, and data represent either both regions or contralateral only.
GFAP Protein Analysis
To quantify GFAP protein in brain and spinal cord, tissues were collected as indicated above and lysates were prepared from contralateral regions according to a modified protocol from Heaven et al. 24 Briefly, tissues were homogenized (1:20,
Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland; Sigma-Aldrich), using a bead mixer mill (GenoGrinder, SPEX SamplePrep), and centrifuged at 17,000 3 g for 20 minutes at 4 8C. The supernatant was collected as the Triton-X-100-soluble fraction. The insoluble pellet was resuspended in an equivalent volume of 6M urea in TEE and centrifuged at 3,000 3 g for 10 minutes at 4 8C. The supernatant was collected as the Triton-X-100-insoluble fraction (urea soluble), and the RF-enriched pellet was resuspended in 2% sodium dodecyl sulfate (SDS) in TEE and boiled for 30 minutes. Protein from each fraction was quantified by bicinchoninic acid (BCA) assay and diluted in PBS with 1mg/ml bovine serum albumin (BSA) and 0.05% Tween 20 as follows: approximately 1 mg/ml Triton-X-100-soluble, 0.01 mg/ml-insoluble, and 0.1 mg/ml RF-enriched protein. GFAP enzyme-linked immunosorbent assays (ELISAs) were performed as previously described for both protein lysates and CSF. 10 
Histology and Immunostaining
For immunofluorescence in the initial time course study in WT mice (see Fig 1) , animals were sacrificed with CO 2 asphyxiation, and brains were collected and bisected at the midline. The contralateral half was immersion fixed in neutral buffered formalin, processed, embedded in paraffin, and sectioned onto slides at 3 mm. Slides were deparaffinized, antigen retrieval was performed in citrate buffer at 100 8C, and sections were blocked in 5% normal goat serum/1% BSA in PBS for 30 minutes. Sections were incubated with 1:1,000 primary rabbit anti-GFAP antibody (Z0334; Dako, Carpinteria, CA) in block for 1 hour at room temperature, rinsed in PBS, and incubated with secondary fluorescent antibody (Thermo Fisher Scientific) for 30 minutes at room temperature. Slides were rinsed in PBS, with one final rinse in water, and dried briefly under an oscillating table fan, and images were generated using a microarray scanner (Agilent Technologies, Santa Clara, CA).
For histology in mutant mice, brains were collected immediately after CSF collection and decapitation. Tissues were immersion fixed in methacarn and processed for paraffin sections and staining with hematoxylin and eosin. For immunofluorescence in mutant mice, animals were anesthetized with isoflurane and transcardially perfused with PBS. Brains were collected and bisected at the midline, the ipsilateral half was immersion fixed in 4% paraformaldehyde overnight at 4 8C and cryoprotected in sucrose, and 30 mm sections were collected with a sliding microtome. Floating sections were blocked in 5% normal goat or donkey serum with 0.3% Triton-X-100 in PBS for 2 hours and incubated with primary antibodies, including rabbit anti-Iba1 (019-19741; Wako Chemicals, Richmond, VA) or goat antidoublecortin (sc-8066; Santa Cruz Biotechnology, Santa Cruz, CA), diluted 1:500 in 1% BSA/0.3% TX-100 for 72 hours at 4 8C. After rinsing in PBS with 0.05% TX-100 (3 times), sections were incubated with secondary antibodies overnight (Alexa Fluor 488-conjugated goat antirabbit or donkey antigoat at 1:500; Invitrogen, Thermo Fisher Scientific), rinsed, and mounted on slides with ProLong Gold with DAPI (Invitrogen, Thermo Fisher Scientific). Fluorescent images were taken with a Nikon (Tokyo, Japan) A1R-Si confocal microscope at equivalent gain and laser power within each experiment.
Luciferase Assay
Tissues from contralateral regions were homogenized (1:20, wt/ vol) in Glo Lysis Buffer (Promega, Madison, WI), and protein was quantified by BCA assay. Luciferase activity was measured with a Turner BioSystems (Sunnyvale, CA) Glo Runner Luminometer using 40 ml of lysate and 40 ml One Glo Plus substrate in a microtiter plate. Relative light units (RLU) were normalized to total milligrams of protein. To measure total GFAP protein, SDS was added for a final concentration of 2% and lysates were boiled for 20 minutes. Protein was quantified and diluted to 0.5 to 2 mg/ml for GFAP ELISA as described above.
Western Analysis
For ubiquitin western blots, 3 mg of RF-enriched protein (described above for ELISA) was analyzed per sample. For pSTAT3 western blots, total protein lysates were prepared by homogenizing tissues (ipsilateral) in 2% SDS, 50mM Tris-HCl (pH 7.4), 5mM EDTA, 1mM PefablocSC with Complete Protease Inhibitor Cocktail and boiling for 20 minutes. Protein was quantified 
Statistics
Statistical analysis was performed with GraphPad (La Jolla, CA) Prism 6 software. For experiments analyzing RNA and protein, an unpaired 2-tailed t test was used to compare treated and untreated mice. A 2-way analysis of variance was used for comparisons of body weights between treatments and genotypes. Tests for each experiment are indicated in the figure legends. Probability values < 0.05 were considered significant.
Results
Identifying Active ASOs Targeting Mouse Gfap
To test astrocyte responsiveness to ASO treatment and whether GFAP suppression could be an effective strategy for treating AxD, ASOs were designed against mouse Gfap, and screened in primary mouse cortical cultures for efficacy. Three of the most promising candidates demonstrated >50% suppression of Gfap transcript in vitro, and were tested further in WT mice via stereotaxic injection into the lateral ventricle (see Fig 1) . The lead ASOs elicited dose-responsive and significant reduction of cortical Gfap mRNA (up to 77% reduction compared to vehicle-treated controls) 2 weeks following a single ICV bolus injection, with ASO-4 and ASO-5 being slightly more effective than ASO-9. For further comparison, ASO-5 and ASO-9 were subjected to a more detailed time course study, testing animals from 1 to 16 weeks following a single injection. Reduction of cortical Gfap mRNA was maximal at 4 weeks postinjection (93%) and persisted to a lesser extent (60%) through the duration of the experiment. Reduction of Gfap mRNA in spinal cord reached >95%, which was sustained through the entire 16-week period. GFAP protein was assessed in mice at 16 weeks postinjection by immunofluorescent staining of sagittal sections using an anti-GFAP antibody, which demonstrated clear reduction at the protein level across all areas examined.
Gfap-Targeted ASOs Reduce Elevated GFAP Transcript and Protein in Mouse Models of AxD
To determine whether Gfap-targeted ASOs could suppress the markedly higher levels of transcript and protein observed in mouse models of AxD, we next tested the effects of treating adult mice after pathology and gliosis are well established. 8 In the Gfap 1/R236H mouse model, RFs are prominent by postnatal day 21 in hippocampus, olfactory bulb, and corpus callosum, as well as subpial, (Fig 2) . Comparable results were observed after treating Gfap
1/R236H
mice and a second mutant line, Gfap 1/R76H , with ASO-4. We tested for specificity by analyzing the mRNA for another type III intermediate filament, peripherin, which exhibits 67 to 70% identity at the RNA level within the GFAP rod domain, and found no evidence of suppression. In addition, treatment with a nonspecific control ASO did not alter Gfap transcript levels in either WT or mutant mice when compared with saline-treated mice. We next tested the degree to which GFAP protein levels in the mutants were reduced, given that the starting point is much higher than WT and the normal halflife of GFAP in vivo is on the order of 1 to 2 months. [25] [26] [27] Using the biochemical criteria of Heaven et al, 24 we analyzed soluble, insoluble, and RF-enriched fractions (see Materials and Methods) after single ASO injections into adult mice. Gfap 1/R236H mice were treated with ASO-5 at 8 weeks of age, and brain and spinal cord were collected 8 weeks postinjection. To our surprise, GFAP was dramatically reduced in all 3 protein fractions in all regions analyzed, including hippocampus, olfactory bulb, cerebral cortex, and cervical spinal cord (Fig 3) . GFAP levels for animals treated with ASO were either below that of saline-treated Gfap 1/1 mice or at the lower limit of detection for the assay. Western analysis of the RF-enriched fraction confirmed that elevation of ubiquitinated proteins in mutant mice is normalized by GFAP suppression (Fig 4A) . In addition, histopathology demonstrated clearance of RFs (see Fig 4B-I) . Elevation of GFAP in AxD brain parenchyma is also reflected in CSF, suggesting that GFAP itself could serve as a useful biomarker to monitor therapeutic response to ASOs. 10, 12 We therefore measured GFAP levels in CSF from adult Gfap 1/R236H mice 8 weeks after treatment with ASO-5. GFAP remained elevated in all mutant mice treated with saline, whereas those receiving ASO had no detectable GFAP in CSF (see Fig 4J) .
Suppression of GFAP in AxD Mice Mitigates Molecular, Cellular, and Clinical Phenotypes
To test whether reduced levels of GFAP transcript and protein alleviate additional phenotypes associated with the R236H mutation, we first measured stress and immune-related transcripts known to be elevated in AxD mice or otherwise associated with gliosis. Elevation of lipocalin-2 (Lcn2) is a consistent feature of astrogliosis, 28 and Lcn2 is also elevated in Gfap 1/R236H mice. Similarly, small chemokines Ccl2 and Cxcl1, microglial Itgb2 (Mac1), the phase II antioxidant response target Nqo1, and the acute-phase protein ceruloplasmin (Cp) are also (Fig 5) . At 2 weeks post-treatment with ASO-5, a time point when Gfap mRNA is clearly suppressed, all of these transcripts were reduced in most regions analyzed. Itgb2 expression was only significantly reduced in olfactory bulb, suggesting that the secondary response by microglia may take longer to normalize. Taken together, the transcription profile indicates astrocytes are beginning to recover as early as 2 weeks post-treatment.
To further assess the extent of astrocyte and CNS recovery, we next analyzed AxD phenotypes at a time point when we know GFAP protein is reduced. Transactivation of the Gfap promoter is another feature of the astrocyte stress response, and contributes to the toxic elevation of GFAP expression. 10, 22 We therefore crossed Gfap 1/R236H mice with a Gfap-luciferase reporter and analyzed mutant and WT littermates 8 weeks after treatment with ASO-4. Analysis of hippocampus, olfactory bulb, and cortex in ASO-treated versus saline-treated mutant mice indicated a significant reduction in Gfap promoter activity in all regions (Fig 6A) . Total GFAP protein levels were also measured, and those from ASO-4-treated mice were at or below levels from salinetreated WT mice (see Fig 6B) , similar to results shown for ASO-5 (see Fig 3) . Furthermore, a simple assessment of body weights at 8 weeks post-treatment shows normalization for ASO-treated mutant mice (Fig 7A) .
We recently demonstrated that the signal transducer and activator of transcription, STAT3, is activated in Gfap 1/R236H mice, 16 and thus could serve as a transcriptional activator of many downstream pathways. AxD mutant mice treated with ASO-5 show reduced STAT3 activation in hippocampus at 8 weeks postinjection, as indicated by western analysis of phospho-Tyr705 (see Fig  7B) . There was no change in pSTAT3 in WT mice treated with ASO versus saline. To determine whether the reduction in proteotoxic stress in astrocytes eventually leads to a decrease in secondary effects on other cell types, we evaluated the microglial response by immunostaining for Iba1 at 8 weeks post-treatment. ASO-treated mutant mice showed a clear decrease in activated microglia compared with those treated with saline, with no apparent increase in ASO-treated WT mice (see Fig 7C) . Previously, we reported that Gfap 1/R236H mice have reduced numbers of proliferating progenitors in the hippocampal subgranular zone, and virtually no new neurons as indicated by fate analysis and doublecortin (DCX) staining. 29 To test for rescue of this phenotype, we analyzed ASO-treated mice for hippocampal DCX expression at 8 weeks postinjection. For these experiments, to avoid potential confounding effects of skewing the ratio of GFAP isoforms, we used ASO-9 to target both the major a isoform and Gfap d (see Fig 1A) , which is prominent in progenitor cells. 30 Immunostaining showed a clear increase of DCX in the granule cell layer of the hippocampus in ASO-treated mutant mice compared to those treated with saline (see Fig 7D) . Both mutant and WT mice treated with ASO show similar staining of DCX-positive neurons compared to WT mice treated with saline. 
Discussion
AxD is caused by dominant gain of function mutations in the gene for GFAP that lead to GFAP accumulation, protein aggregation, gliosis, and non-cell-autonomous toxicity in the CNS. We propose that GFAP knockdown using antisense technology is a viable approach for treating AxD. In this report, we have shown that bolus delivery of ASOs to the ventricular system of adult mice results in rapid and long-lasting suppression of GFAP mRNA and protein. The same treatment administered to AxD-mice with elevated levels of GFAP and established astrocyte pathology reduces both mRNA and protein below WT levels, reverses pathology, and rescues downstream markers of disease.
Mutant GFAP activates stress and immune-related responses that lead to astrogliosis and the associated transactivation of Gfap transcription. 8, 10, 31 Previous work using cell culture models of AxD suggested that proteasome function is also impaired, likely by GFAP oligomers in the soluble fraction. 32 Studies with brain lysates from mouse models and patients with AxD showed a marked increase in high-molecular-weight ubiquitinated proteins, again implying proteasomal dysfunction. 11 We have hypothesized that elevated transcription and reduced degradation are both culprits in the accumulation of GFAP. Because even normal GFAP is a long-lived protein, with a half-life in vivo estimated at 1 to 2 months, 25-27 a key question is whether antisense suppression of Gfap transcript can be sustained for a long enough period to allow for protein degradation. Our results show that ASO-targeted transcript suppression leads to nearly complete elimination of GFAP protein, including insoluble aggregate forms, within a relatively short period of time. These results are consistent with our recent finding that the turnover rate of GFAP in mutant mice is actually faster than in WT. 25 The rapid clearance of GFAP and other ubiquitinated proteins suggests that the proteasome system can recover once new mutant protein is no longer being produced. Experiments are underway to determine a more specific timeline of when GFAP mRNA and protein decrease and return after ASO treatment. Although we do not understand the mechanism behind the weight differences in these mice, it will be interesting to see whether weight loss occurs upon the return of mutant GFAP. The AxD model mice used in the current study, designed with knockin mutations in the endogenous Gfap gene, display many features in common with the human disease, at both the pathological (RFs, mislocalization of TDP-43) and biochemical (activation of stress pathways, inhibition of the proteasome, changes in expression of cytokine and transporter genes) levels. Nevertheless, they have no evident changes in white matter, and thus do not have a leukodystrophy. Some have suggested that these models more closely resemble the adult or type II forms of the disease, 33, 34 and it is an open question whether GFAP suppression can effectively correct myelin deficits such as those that are prominent in type I patients. Gfap transcripts include several different isoforms, with a and d being the most prominent in the CNS. 30 Two of the ASOs in this study (ASO-4, ASO-5) target the major Gfap isoform a, whereas the third (ASO-9) targets both a and d (see Fig 1A) . Although in vitro analysis has shown that shifting the ratios between a and d can lead to GFAP aggregation, 35 our experiments suggest this is not the case in vivo. Both ASO-4 and ASO-5 cleared protein aggregates, and led to similar phenotypic outcomes as ASO-9 (see Fig 7A) . Given that the role of GFAP d is still unknown, these ASOs provide the tools for manipulating Gfap isoforms in vivo and for additional studies to confirm whether both isoforms should be targeted for therapy in humans. Elimination of GFAP, whether by genetic knockout or ASO targeting, has no obvious detrimental effects in mice under normal circumstances. Here, we show improved body condition in AxD mutant mice with 2 different ASOs. However, there are studies of genetic knockouts showing increased susceptibility to infection, injury, kainate-induced seizures, and experimental autoimmune encephalomyelitis. 6, [36] [37] [38] [39] [40] Although the current work demonstrates proof of concept, one goal of our continued preclinical studies is to titrate the dose of ASO and determine the level of suppression necessary to achieve clinical improvement. Similar experiments have been performed in WT animals, but given the differences in protein level and turnover rate, dose-response studies in mutant animals will be essential. In addition, it will be important to assess improvements in behavioral phenotypes such as the cognitive deficits observed in models of AxD. 29 Another key finding in this study was the concomitant reduction of GFAP in CSF, indicating that GFAP itself could be used as a biomarker to assess ASO efficacy and duration of suppression. 10, 12 How closely linked the temporal changes in CSF are to those in brain remains to be determined, but these results suggest progress could be monitored longitudinally. We have also reported that GFAP is elevated in blood of some patients with AxD, 12 and improved methods for astrocyte exosome purification [41] [42] [43] may increase the utility of this more accessible body fluid for analysis. Antisense therapy has become a realistic approach for treating neurodegenerative disease, and transcript targeting strategies range from RNase H-mediated degradation, as demonstrated in this and other reports, to other applications that alter splicing and restore functional protein as in SMA. 18 The mechanism of cellular uptake of ASOs is also varied. Although the process commonly involves clathrin-or caveolin-dependent mechanisms, ASOs may also be taken in by nonconventional endocytic pathways, and the route of entry can affect efficacy. 44 Although ASO uptake by astrocytes has been shown previously, 45 here we use a primary disorder of astrocytes to demonstrate the efficacy of ASOs in both normal and dysfunctional reactive astrocytes. With the increasing interest in targeting astrocytes in other disorders of the CNS, 46 ,47 these results demonstrate that antisense therapy can alleviate the non-cell-autonomous toxicity mediated by dysfunctional astrocytes. In summary, these studies demonstrate ASO efficacy in astrocytes, open up new approaches for investigating the biology of intermediate filaments in vivo, and most importantly provide the foundation for developing GFAP therapeutics for patients with AxD.
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